Limits...
Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis.

Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T, Rong X - Sci Rep (2015)

Bottom Line: Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer.Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease.Moreover, legumain overexpression was correlated with poor prognosis and clinical stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Tumor Molecular Biology, Nankai University School of Medicine, Tianjin 371000, China.

ABSTRACT
Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer. We searched the Cochrane Library, PubMed, Embase, and EBSCO databases and the Wangfang and CNKI databases in China by using "legumain" and ("neoplasms" OR "cancer") as search terms. We included case-controlled studies of legumain and cancer. The quality of the studies was evaluated by using Lichtenstein's guidelines, and valid data was extracted for analysis. In total, 10 articles were included in this study. Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease. Moreover, legumain overexpression was correlated with poor prognosis and clinical stage. Furthermore, Cancer Genome Atlas data showed that among patients with rectal cancer, those with tumors overexpressing legumain had shorter overall survival than those in the low expression group (P < 0.05). Legumain appears to be involved in tumor development and deterioration; thus, it can potentially be developed into both a marker for monitoring and diagnosing tumors and a therapeutic target.

No MeSH data available.


Related in: MedlinePlus

Forest plot of risk ratios of legumain overexpression in N0 vs N+ groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4660395&req=5

f3: Forest plot of risk ratios of legumain overexpression in N0 vs N+ groups.

Mentions: Four articles compared LGMNHigh rates in patients without (N0; 20.0%; 494 cases) and with (N+; 33.8%; 423 cases) lymph node metastases6131821. Since the studies were significantly heterogeneous (P < 0.10, I2 = 85%), we used the random-effect model for pooled analysis. The results revealed no significant differences between the two groups (RR = 0.66, 95% CI: 0.36–1.20; P > 0.05; Fig. 3). Thus, this analysis showed that the LGMNHigh percentage in the N0 group was similar to that in the N+ group.


Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis.

Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T, Rong X - Sci Rep (2015)

Forest plot of risk ratios of legumain overexpression in N0 vs N+ groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4660395&req=5

f3: Forest plot of risk ratios of legumain overexpression in N0 vs N+ groups.
Mentions: Four articles compared LGMNHigh rates in patients without (N0; 20.0%; 494 cases) and with (N+; 33.8%; 423 cases) lymph node metastases6131821. Since the studies were significantly heterogeneous (P < 0.10, I2 = 85%), we used the random-effect model for pooled analysis. The results revealed no significant differences between the two groups (RR = 0.66, 95% CI: 0.36–1.20; P > 0.05; Fig. 3). Thus, this analysis showed that the LGMNHigh percentage in the N0 group was similar to that in the N+ group.

Bottom Line: Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer.Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease.Moreover, legumain overexpression was correlated with poor prognosis and clinical stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Tumor Molecular Biology, Nankai University School of Medicine, Tianjin 371000, China.

ABSTRACT
Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer. We searched the Cochrane Library, PubMed, Embase, and EBSCO databases and the Wangfang and CNKI databases in China by using "legumain" and ("neoplasms" OR "cancer") as search terms. We included case-controlled studies of legumain and cancer. The quality of the studies was evaluated by using Lichtenstein's guidelines, and valid data was extracted for analysis. In total, 10 articles were included in this study. Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease. Moreover, legumain overexpression was correlated with poor prognosis and clinical stage. Furthermore, Cancer Genome Atlas data showed that among patients with rectal cancer, those with tumors overexpressing legumain had shorter overall survival than those in the low expression group (P < 0.05). Legumain appears to be involved in tumor development and deterioration; thus, it can potentially be developed into both a marker for monitoring and diagnosing tumors and a therapeutic target.

No MeSH data available.


Related in: MedlinePlus